Literature DB >> 29932787

Location matters in early stage nodal diffuse large B-cell lymphoma.

Konstantinos Lontos1, Anastasia Tsagianni2, Jian-Min Yuan3, Daniel P Normolle4, Michael Boyiadzis1, Jing-Zhou Hou5, Steven H Swerdlow6, Kathleen A Dorritie1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29932787      PMCID： PMC6744257          DOI： 10.1080/10428194.2018.1471600

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  10 in total

1.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Authors:  Michael Crump; Sattva S Neelapu; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Jason Westin; Brian K Link; Annette Hay; James R Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew J Maurer; Lynn Navale; Jeff Wiezorek; William Y Go; Christian Gisselbrecht
Journal:  Blood       Date:  2017-08-03       Impact factor: 22.113

2.  Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.

Authors:  Jorge J Castillo; Eric S Winer; Adam J Olszewski
Journal:  Am J Hematol       Date:  2014-02-19       Impact factor: 10.047

3.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

4.  Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults.

Authors:  Itziar Salaverria; Claudia Philipp; Ilske Oschlies; Christian W Kohler; Markus Kreuz; Monika Szczepanowski; Birgit Burkhardt; Heiko Trautmann; Stefan Gesk; Miroslaw Andrusiewicz; Hilmar Berger; Miriam Fey; Lana Harder; Dirk Hasenclever; Michael Hummel; Markus Loeffler; Friederike Mahn; Idoia Martin-Guerrero; Shoji Pellissery; Christiane Pott; Michael Pfreundschuh; Alfred Reiter; Julia Richter; Maciej Rosolowski; Carsten Schwaenen; Harald Stein; Lorenz Trümper; Swen Wessendorf; Rainer Spang; Ralf Küppers; Wolfram Klapper; Reiner Siebert
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

5.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Authors:  Bertrand Coiffier; Catherine Thieblemont; Eric Van Den Neste; Gérard Lepeu; Isabelle Plantier; Sylvie Castaigne; Sophie Lefort; Gérald Marit; Margaret Macro; Catherine Sebban; Karim Belhadj; Dominique Bordessoule; Christophe Fermé; Hervé Tilly
Journal:  Blood       Date:  2010-06-14       Impact factor: 22.113

Review 6.  Staging non-Hodgkin lymphoma.

Authors:  James O Armitage
Journal:  CA Cancer J Clin       Date:  2005 Nov-Dec       Impact factor: 508.702

7.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

8.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

9.  Comparing national cancer registries: The National Cancer Data Base (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program.

Authors:  Sanjay Mohanty; Karl Y Bilimoria
Journal:  J Surg Oncol       Date:  2014-01-25       Impact factor: 3.454

10.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.

Authors:  T P Miller; S Dahlberg; J R Cassady; D J Adelstein; C M Spier; T M Grogan; M LeBlanc; S Carlin; E Chase; R I Fisher
Journal:  N Engl J Med       Date:  1998-07-02       Impact factor: 91.245
  10 in total
  2 in total

1.  CD30 Expression in Oral and Oropharyngeal Diffuse Large B Cell Lymphoma, not Otherwise Specified.

Authors:  Ana Luísa Morais-Perdigão; Carla Isabelly Rodrigues-Fernandes; Gabriela Ribeiro Araújo; Ciro Dantas Soares; Bruno Augusto Benevenuto de Andrade; Manoela Domingues Martins; Pablo Agustin Vargas; Hélder Antônio Rebelo Pontes; Fábio Ramôa Pires; Rommel Mario Rodríguez Burbano; Felipe Paiva Fonseca
Journal:  Head Neck Pathol       Date:  2021-10-16

2.  Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015.

Authors:  Sara J Schonfeld; Lindsay M Morton; Amy Berrington de González; Rochelle E Curtis; Cari M Kitahara
Journal:  Cancer Epidemiol       Date:  2019-12-26       Impact factor: 2.984
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.